T-cell Immunity and Viral Pathogenicity on Vaccine Efficacy
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 4023
Special Issue Editors
Interests: anti-viral drugs; HIV-1 pathgenicity
Interests: allergy and asthma; autoimmune diseases; clinical immunology; exosomes; extracellular vesicles; immune regulation via miRNAs; immune-related disorders; mechanisms underlying hypersensitivity reactions
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to announce the Special Issue of “T Cell Immunity and HIV-1 Pathogenicity”, to open a discussion on the development of two vaccines: the COVID and AIDS vaccines. The discussion is held on the levels of microbial, immune, and social sciences.
The central theme of discussion is the role of T-cell and HIV pathogenicity in the development of vaccines. We consider that HIV-1 replication in CD4 T-cells, but not in CD8 T-cells or B-cells, is the key issue in the effective AIDS vaccine development though macrophages can also be infected. With the functional host CD4 T-cells, COVID vaccines were developed in a 10-month period built on four-decades of HIV/AIDS study.
We welcome research articles, reviews, and perspectives that examine, study and contribute conceptually in the development of COVID and effective AIDS vaccines. In the effort to be spearheaded by the editorial office, we will transform the contributions into deep knowledge of vaccinology, and apply Applied Science to further the vaccine development. Contributions in the following are welcome:
- Studies on the relationship of cytokine storm with the spike protein and/or SARS-CoV-2 replication in lung, kidney or other target organs/tissues
- Studies of T-cell, B-cell immune response against the spike proteins of SARS-CoV-2 before and/or after COVID vaccine immunization
- Studies of Kick-Kill (Shock-Kill) and Block-Lock on HIV cure, and/or the strategies on vaccines for HIV cure
- Model, technology on study of HIV-1 or SARS-CoV-2 pathogenicity
We look forward to hearing from you!
Prof. Dr. Clyde S. Crumpacker
Prof. Dr. Philip W. Askenase
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HIV-1
- AIDS
- SARS-CoV-2
- COVID-19
- cytokine storm
- host immunity
- vaccine
- vaccination
- multi-omic technology
